Robey RW, Polgar O, Deeken J, To KW, Bates SEABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 26: 39-57

Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Cancer and metastasis reviews (Impact Factor: 7.23). 04/2007; 26(1):39-57. DOI: 10.1007/s10555-007-9042-6
Source: PubMed


Multidrug resistance is a major obstacle to successful cancer treatment. One mechanism by which cells can become resistant to chemotherapy is the expression of ABC transporters that use the energy of ATP hydrolysis to transport a wide variety of substrates across the cell membrane. There are three human ABC transporters primarily associated with the multidrug resistance phenomenon, namely Pgp, MRP1, and ABCG2. All three have broad and, to a certain extent, overlapping substrate specificities, transporting the major drugs currently used in cancer chemotherapy. ABCG2 is the most recently described of the three major multidrug-resistance pumps, and its substrates include mitoxantrone, topotecan, irinotecan, flavopiridol, and methotrexate. Despite several studies reporting ABCG2 expression in normal and malignant tissues, no trials have thus far addressed the role of ABCG2 in clinical drug resistance. This gives us an opportunity to critically review the disappointing results of past clinical trials targeting Pgp and to propose strategies for ABCG2. We need to know in which tumor types ABCG2 contributes to the resistance phenotype. We also need to develop standardized assays to detect ABCG2 expression in vivo and to carefully select the chemotherapeutic agents and clinical trial designs. This review focuses on our current knowledge about normal tissue distribution, tumor expression profiles, and substrates and inhibitors of ABCG2, together with lessons learned from clinical trials with Pgp inhibitors. Implications of SNPs in the ABCG2 gene affecting the pharmacokinetics of substrate drugs, including many non-chemotherapy agents and ABCG2 expression in the SP population of stem cells are also discussed.

20 Reads
  • Source
    • "ABCG2 is localized apically in polarized cells, such as blood– brain barrier and intestinal enterocytes, where it can influence the oral absorption and pharmacokinetics of several anticancer drugs [7] [8]. Human ABCG2 has a broad substrate profile that includes several anticancer drugs, ranging from organic anion conjugates, nucleoside analogs, organic dyes, and tyrosine kinase inhibitors (TKIs) to anthracyclines [9] [10]. Although evidence of ABCG2 involvement in clinical MDR is accumulating, there is no lack of conflicting results between ABCG2 expression and drug response [11] [12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Multidrug resistance (MDR) is a phenomenon where cancer cells become simultaneously resistant to anticancer drugs with different structures and mechanisms of action. MDR has been shown to be associated with overexpression of ATP-binding cassette (ABC) transporters. Here, we report that telatinib, a small molecule tyrosine kinase inhibitor, enhances the anticancer activity of ABCG2 substrate anticancer drugs by inhibiting ABCG2 efflux transporter activity. Co-incubation of ABCG2-overexpressing drug resistant cell lines with telatinib and ABCG2 substrate anticancer drugs significantly reduced cellular viability, whereas telatinib alone did not significantly affect drug sensitive and drug resistant cell lines. Telatinib at 1μM did not significantly alter the expression of ABCG2 in ABCG2-overexpressing cell lines. Telatinib at 1μM significantly enhanced the intracellular accumulation of [(3)H]-mitoxantrone (MX) in ABCG2-overexpressing cell lines. In addition, telatinib at 1μM significantly reduced the rate of [(3)H]-MX efflux from ABCG2-overexpressing cells. Furthermore, telatinib significantly inhibited ABCG2-mediated transport of [(3)H]-E217βG in ABCG2 overexpressing membrane vesicles. Telatinib stimulated the ATPase activity of ABCG2 in a concentration-dependent manner, indicating that telatinib might be a substrate of ABCG2. Binding interactions of telatinib were found to be in transmembrane region of homology modeled human ABCG2. In addition, telatinib (15mg/kg) with doxorubicin (1.8mg/kg) significantly decreased the growth rate and tumor size of ABCG2 overexpressing tumors in a xenograft nude mouse model. These results, provided that they can be translated to humans, suggesting that telatinib, in combination with specific ABCG2 substrate drugs may be useful in treating tumors that overexpress ABCG2.
    Biochemical pharmacology 02/2014; 89(1). DOI:10.1016/j.bcp.2014.02.012 · 5.01 Impact Factor
  • Source
    • "Studies of the pharmacological interactions between ABCG2/BCRP and molecular-targeted kinase inhibitors have revealed that clinically used kinase inhibitors are in vivo substrates and/or inhibitors of this ABC transporter. Gefitinib is an orally administered, active, selective epidermal growth factor receptor tyrosine kinase inhibitor (TKI) used to treat patients with advanced non-small-cell lung cancer (NSCLC),129,130 and ABCG2/BCRP is expressed in intestinal epithelial cells and at the blood–brain and blood–cerebrospinal barriers, where it restricts the penetration of the brain by xenobiotics.65,131 Stewart et al98 showed that the oral bioavailability of irinotecan, a good substrate of ABCG2/BCRP, is affected by the oral administration of gefitinib. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Adenine triphosphate (ATP)-binding cassette (ABC) transporter proteins, such as ABCB1/P-glycoprotein (P-gp) and ABCG2/breast cancer resistance protein (BCRP), transport various structurally unrelated compounds out of cells. ABCG2/BCRP is referred to as a "half-type" ABC transporter, functioning as a homodimer, and transports anticancer agents such as irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), gefitinib, imatinib, methotrexate, and mitoxantrone from cells. The expression of ABCG2/BCRP can confer a multidrug-resistant phenotype on cancer cells and affect drug absorption, distribution, metabolism, and excretion in normal tissues, thus modulating the in vivo efficacy of chemotherapeutic agents. Clarification of the substrate preferences and structural relationships of ABCG2/BCRP is essential for our understanding of the molecular mechanisms underlying its effects in vivo during chemotherapy. Its single-nucleotide polymorphisms are also involved in determining the efficacy of chemotherapeutics, and those that reduce the functional activity of ABCG2/BCRP might be associated with unexpected adverse effects from normal doses of anticancer drugs that are ABCG2/BCRP substrates. Importantly, many recently developed molecular-targeted cancer drugs, such as the tyrosine kinase inhisbitors, imatinib mesylate, gefitinib, and others, can also interact with ABCG2/BCRP. Both functional single-nucleotide polymorphisms and inhibitory agents of ABCG2/BCRP modulate the in vivo pharmacokinetics and pharmacodynamics of these molecular cancer treatments, so the pharmacogenetics of ABCG2/BCRP is an important consideration in the application of molecular-targeted chemotherapies.
    Pharmacogenomics and Personalized Medicine 02/2014; 7(1):53-64. DOI:10.2147/PGPM.S38295
  • Source
    • "It is one of the major ABC transporters contributing to the MDR phenotype. Overexpression of the ABCG2 gene is frequently observed in cancer cell lines selected with chemotherapeutic drugs [2,45]. To date, most studies examining the regulation of ABCG2 have focused on transcription. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Multidrug resistance (MDR) is a major obstacle to successful cancer treatment. It is often associated with an increased efflux of a variety of structurally unrelated anticancer drugs by ATP-binding cassette (ABC) transporters including P-gp, ABCG2 and MRP1. MicroRNAs (miRNAs) are small non-coding RNAs that govern posttranscriptional regulation of target genes by interacting with specific sequences in their 3[prime] untranslated region (3[prime]UTR), thereby promoting mRNA degradation or suppressing translation. Accumulating evidence suggests that alterations in miRNAs contribute to resistance to anticancer drugs. While miRNAs are well-known to be dysregulated in cancer, recent literature revealed that miRNA levels in biological samples may be correlated with chemotherapy response. This review summarized the coordinated network by which miRNA regulated MDR transporters. The usefulness of miRNAs as prognostic biomarkers for predicting chemotherapeutic outcome is discussed. MiRNAs may also represent druggable targets for circumvention of MDR.
    Journal of Biomedical Science 12/2013; 20(1):99. DOI:10.1186/1423-0127-20-99 · 2.76 Impact Factor
Show more